Objectif Cancer is a leading cause of death worldwide. Fortunately an abundance of cancer drugs are becoming available; the challenge now is to select the most promising. Integrated cancer research and biomarker-driven adaptive and hypothesis-testing clinical trials are imperative. Many tumor characteristics can now be visualized simultaneously, but the necessary tracers have hardly been explored clinically. In the onQview program, we aim to create a drug development strategy based on a novel non-radioactive molecular imaging approach to guide patient-tailored selection of drugs, to measure in vivo drug and tumor behavior, and to allow dynamic treatment tuning. Our extensive (pre)clinical experience with molecular imaging and drug development is hereby merged with our unique infrastructure, including lasers, microscopes, and advanced detection systems for non-ionizing electromagnetic waves, for optical and photoacoustic imaging modalities. We will develop novel non-radioactive tracers based on HER-targeting drugs in breast and colon cancer, and use molecular imaging to track the drugs and corresponding effect sensors that visualize targeting effects. This approach will allow dynamic treatment tuning in pre-clinical (animal) experiments. We will also advance the implementation of optical and photoacoustic imaging with optimized measurement techniques and quantification strategies that will allow testing of the new tracers in breast/colon cancer models. Two tracers will be produced for human use and evaluated in clinical studies that enable visualization of drug behavior, drug targets and drug effects in relation to the HER family in breast and colon cancer. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencesphysical sciencesopticsmicroscopymedical and health sciencesclinical medicineoncologycolorectal cancerengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsnatural sciencesphysical sciencesopticslaser physics Programme(s) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Thème(s) ERC-AG-ID1 - ERC Advanced Grant Interdisciplinary Panel Appel à propositions ERC-2011-ADG_20110310 Voir d’autres projets de cet appel Régime de financement ERC-AG - ERC Advanced Grant Institution d’accueil ACADEMISCH ZIEKENHUIS GRONINGEN Contribution de l’UE € 1 797 749,40 Adresse HANZEPLEIN 1 9713 GZ Groningen Pays-Bas Voir sur la carte Région Noord-Nederland Groningen Overig Groningen Type d’activité Higher or Secondary Education Establishments Contact administratif Gerda G. Klooster (Dr.) Chercheur principal Emma Geertruida Elisabeth De Vries (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Bénéficiaires (2) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire ACADEMISCH ZIEKENHUIS GRONINGEN Pays-Bas Contribution de l’UE € 1 797 749,40 Adresse HANZEPLEIN 1 9713 GZ Groningen Voir sur la carte Région Noord-Nederland Groningen Overig Groningen Type d’activité Higher or Secondary Education Establishments Contact administratif Gerda G. Klooster (Dr.) Chercheur principal Emma Geertruida Elisabeth De Vries (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée UNIVERSITEIT TWENTE Pays-Bas Contribution de l’UE € 702 240,00 Adresse DRIENERLOLAAN 5 7522 NB Enschede Voir sur la carte Région Oost-Nederland Overijssel Twente Type d’activité Higher or Secondary Education Establishments Contact administratif Ferdinand Damhuis (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée
